Vyne halts skin disease drug trial after failure; shares plunge

YARROW BIOSCIENCE

30/07/2025 15:10

** Shares of VYNE Therapeutics VYNE.O plummet 72% to an all-time low of 40 cents

** Stock set for its worst day in over 7 years, if losses hold

** Co says its skin disease drug, Repibresib gel, for vitiligo failed to meet its mid-stage trial goals, of improving facial vitiligo by at least 50% or 75%

** VYNE will halt the trial's ongoing extension phase and seek an external partner to continue developing Repibresib

** Repibresib gel caused more mild skin side effects and application site pain than placebo, co says

** Co had about $39.6 million in cash as of June 30

** Including session's move, stock down 88% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))